Eli Lilly and Company stock: Barclays raises target to $1,550
Published on 11/17/2026 at 16:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBarclays sees further growth potential
- Barclays cited Bridge uptake, international demand and market-share gains after Lilly's third-quarter report.
- The Overweight rating was maintained as the analyst assessed Lilly's underlying growth prospects.
- The shares traded below the prior Xetra close in late Tuesday afternoon trading.
Barclays raised its Eli Lilly price target to 1,550 US dollars from 1,400 US dollars on Monday, November 16, 2026, while keeping an Overweight rating. Markets Insider reported the analyst action, citing a research note from Barclays analyst Emily Field.
Barclays points to underlying demand
Barclays kept its Overweight view after Lilly's third-quarter report. The note pointed to Bridge uptake, international demand and market-share gains as signs of further growth potential.
The analyst also acknowledged that one-time benefits helped the quarter. That distinction leaves investors focused on whether demand and commercial execution can sustain Lilly's expansion beyond individual reporting-period effects.
Late trading remains below Xetra
Eli Lilly and Company stock traded at 1,293.80 euros on Lang & Schwarz at 16:03 CET on Tuesday, November 17, 2026, 2.00 percent below the Xetra close of Monday, November 16, 2026, at 1,320.20 euros. The current German-market quotation followed a 0.61 percent increase from the 1,285.90-euro Lang & Schwarz quote in the earlier report published at 13:32 CET on Tuesday.
Eli Lilly and Company stock facts
- Company: Eli Lilly and Company
- ISIN: US5324571083
- US ticker: LLY
- Primary exchange: New York Stock Exchange
- Lang & Schwarz quote: 1,293.80 euros at 16:03 CET on November 17, 2026
- Xetra close: 1,320.20 euros on November 16, 2026
- Sector: Pharmaceuticals
US equities were the broader market context for Eli Lilly, with current market developments covered in Current market reports.
For investors, the next focus is whether commercial uptake and international demand support the growth case reflected in Barclays' revised target. More news and analyses on Eli Lilly and Company stock.
